The Investment Column: Scotia scrabbles for a success
Thursday 25 September 1997
Though the deal breathed new life into Scotia's shares, which picked up a further 18.5p to 436p on yesterday's interim results, the price has still not recovered from the news in March that Tarabetic, Scotia's lead drug for diabetic nerve damage, which has been under development since 1991, failed to win UK approval. That announcement lopped almost a quarter off the group's value in a day.
Scotia must prove that it can turn evening primrose oil into real prescription drugs, not just food supplements and treatments for ailments such as eczema. Most other drug groups have already dismissed oil-based technology in favour of proteins. The question is whether Scotia knows something that the others do not.
The company believes that Tarabetic will eventually get approval. It is equally confident about its treatment for cancer, codenamed EF13, and EF5 for arthritis. However recent news that EF5 does not work in one group of trial patients is hardly reassuring.
The technology needs to work if Scotia is to justify the money it is ploughing into research and marketing. Increases in these costs in the half-year to June meant operating losses deepened by almost three-quarters to pounds 13m. Even its pounds 60m of available cash is only enough to last two years. That Scotia is already scrabbling for new ways to raise funds - like a Nasdaq listing or spinning off its fast-growing nutrients business - sits uncomfortably with the view of David Horrobin, chief executive, that Scotia will be cash-positive by 2000. Until Scotia scores a drug success, the shares are high enough.
- 1 Drugs Live cannabis trial: Hash is less harmful than any other drug, expert claims
- 2 Have sex with your iPad thanks to the new sex toy no-one asked for
- 3 The 'sex selfie stick' lets you FaceTime the inside of a vagina
- 5 Why you're almost certainly more like your father than your mother
Out-of-touch MPs ‘don’t get it’, says ex-Civil Service chief
Mark Zuckerberg: Facebook CEO's one simple test for who to hire
Bali nine: Welcome to 'Execution Island' – the Indonesian holiday resort where foreigners are sent to die
'A girl is more responsible for rape than a boy': The statement that shocked the world... except India
The 'sex selfie stick' lets you FaceTime the inside of a vagina
Durham Free School: 'Creationism taught at' free school facing closure
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
Ukip would cut billions from Scottish budget to fund English tax cuts
End of the licence fee: BBC to back radical overhaul of how it is funded
Ukraine crisis: Top Chinese diplomat backs Putin and says West should 'abandon zero-sum mentality'
Boris Nemtsov shot dead: Outspoken Putin critic who had expressed fears for his life is killed near the Kremlin
iJobs Money & Business
£8 per hour: Recruitment Genius: This Pension Specialist was established early...
£30 - 35k + Bonus & Benefits: Guru Careers: We are seeking an Executive Assist...
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...
Voluntary post, reasonable expenses reimbursed: Reach Volunteering: Would you ...